In vivo biodistribution analysis of transmission competent and defective RNA virus-based episomal vector

RNA virus-based episomal vector (REVec) is an emerging viral vector system that mediates long-term stable gene expression in variety of cell types in vitro . However, little is known about its tissue tropism and persistence of gene expression in vivo . Here, to evaluate the feasibility of REVec for...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Scientific reports Ročník 10; číslo 1; s. 5890 - 12
Hlavní autori: Komatsu, Yumiko, Tanaka, Chiaki, Komorizono, Ryo, Tomonaga, Keizo
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London Nature Publishing Group UK 03.04.2020
Nature Publishing Group
Nature Portfolio
Predmet:
ISSN:2045-2322, 2045-2322
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:RNA virus-based episomal vector (REVec) is an emerging viral vector system that mediates long-term stable gene expression in variety of cell types in vitro . However, little is known about its tissue tropism and persistence of gene expression in vivo . Here, to evaluate the feasibility of REVec for in vivo gene delivery, we conducted biodistribution analysis of transmission competent REVec and transmission defective ΔG-REVec in Lewis rats. Following intracranial administration of REVec, transgene expression was detected in various tissues. In contrast, transgene expression was only observed in the brain after ΔG-REVec administration. Low levels of vector shedding in the feces and blood and of neutralizing antibody in the serum were detected after REVec injection. In the brain, microglia, astrocytes and neurons were susceptible to REVec-mediated transduction. However, the animals administered with REVec, but not with ΔG-REVec showed a significant decrease in body weight compared to mock treated animals. Additionally, CD8 T cell infiltration was observed in the brain of these animals. In summary, we demonstrated that REVec promotes long-term transgene expression in vivo without causing high vector shedding or neutralizing antibody production; however, suggests the need to attenuate vector associated pathogenicity in the future.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-020-62630-7